The immunosuppressive IgA+TIBs are also relevant for clinical situation: based on the analysis of RNA-Seq data from TCGA, we have previously observed association of high IgA/IgG1 ratio with worse survival in melanoma patients (11) and bladder cancer patients receiving immunotherapy (11, 12). Here, CD79A is linked to melanoma.